Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $792.26 million. The enterprise value is $445.42 million.
Important Dates
The next estimated earnings date is Monday, May 5, 2025, after market close.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 106.63 million shares outstanding. The number of shares has increased by 12.85% in one year.
| Current Share Class | 106.63M |
| Shares Outstanding | 106.63M |
| Shares Change (YoY) | +12.85% |
| Shares Change (QoQ) | +3.58% |
| Owned by Insiders (%) | 2.35% |
| Owned by Institutions (%) | 84.86% |
| Float | 80.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 1.73 |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.30, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.30 |
| Quick Ratio | 9.15 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -144.86 |
Financial Efficiency
Return on equity (ROE) is -54.14% and return on invested capital (ROIC) is -33.94%.
| Return on Equity (ROE) | -54.14% |
| Return on Assets (ROA) | -31.22% |
| Return on Invested Capital (ROIC) | -33.94% |
| Return on Capital Employed (ROCE) | -56.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$865,371 |
| Employee Count | 299 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.63% in the last 52 weeks. The beta is 1.00, so RCKT's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -68.63% |
| 50-Day Moving Average | 7.99 |
| 200-Day Moving Average | 14.34 |
| Relative Strength Index (RSI) | 54.89 |
| Average Volume (20 Days) | 4,254,203 |
Short Selling Information
The latest short interest is 12.44 million, so 11.66% of the outstanding shares have been sold short.
| Short Interest | 12.44M |
| Short Previous Month | 11.05M |
| Short % of Shares Out | 11.66% |
| Short % of Float | 15.40% |
| Short Ratio (days to cover) | 6.83 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -273.21M |
| Pretax Income | -253.26M |
| Net Income | -258.75M |
| EBITDA | -263.83M |
| EBIT | -273.21M |
| Earnings Per Share (EPS) | -$2.73 |
Full Income StatementBalance Sheet
The company has $372.34 million in cash and $25.50 million in debt, giving a net cash position of $346.84 million or $3.25 per share.
| Cash & Cash Equivalents | 372.34M |
| Total Debt | 25.50M |
| Net Cash | 346.84M |
| Net Cash Per Share | $3.25 |
| Equity (Book Value) | 463.23M |
| Book Value Per Share | 4.35 |
| Working Capital | 337.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$209.72 million and capital expenditures -$5.86 million, giving a free cash flow of -$215.59 million.
| Operating Cash Flow | -209.72M |
| Capital Expenditures | -5.86M |
| Free Cash Flow | -215.59M |
| FCF Per Share | -$2.02 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |